Concizumab
Based on 1 publication(s) in Google Scholar
Concizumab is an anti-TFPI monoclonal antibody (IgG4 type) that binds to the Kunitz-type protease inhibitor (KPI) 2 structural domain of TFPI, thereby blocking the interaction of this structural domain with the FXa active site. Concizumab can be used in the study of haemophilia.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 98.12%
- CAS 番号: 1312299-39-0
- 分子量:146.28 kDa
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
MedChemExpress（MCE）の使用を引用している文献 Concizumab
More
生物活性
Human IgG4 kappa
Human
TFPI
| Parameter | Unit | Estimate | %RSE |
| CLL | mL/h/kg | 0.14 | 6.1 |
| V1 | mL/kg | 33 | 34 |
| V2 | mL/kg | 33 | - |
| Q | mL/h/kg | 0.12 | 16 |
| F | % | 93 | 7.7 |
| Vmax | µg/h/kg | 11 | 17 |
| Km | µg/mL | 0.54 | 52 |
| t1/2(abs) | h | 72 | 32 |
CLL: the linear part of the clearance.
V1: the volume of the central compartment.
V2: the volume of the peripheral compartment.
Vmax: the maximum amount of anti-TFPI cleared per time unit via binding to TFPI.
Km: the concentration at which the target mediated elimination rate is 50% of the maximum value (Vmax).
T1/2(abs): the absorption half-life, describing the rate of absorption after sc administration.
%RSE: residual standard error.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Cynomolgus monkeys (target mediated drug disposition (TMDD) model)[2].
-
Dosage:20mg/kg or 200 mg/kg
-
Administration:Intravenous injection/subcutaneous injection
-
Result:Showed a high bioavailability (93%) and the absorption half-life is estimated to be 72 h.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG4 kappa
ELISA, FACS, Functional assay
-
Flow cytometric analysis of 1.5X106 HEPG2 cells with Concizumab (HY-P99283, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG4 (S228P) kappa, Isotype Control (HY-P99003, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
化学情報
-
CAS 番号 1312299-39-0
-
性状 Liquid
-
分子量 146.28 kDa
-
Color Colorless to light yellow
-
SMILES
[Concizumab]
-
別名
NN 7415; mAb 2021; Anti-TFPI Recombinant Antibody
-
輸送条件
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Thromb Res
2024 Dec:244:109208. PMID: 39522336
純度とドキュメンテーション
-
データシート (262 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
参考文献
[1]. Kjalke M, et al. Thrombin generation potential in the presence of concizumab and rFVIIa, APCC, rFVIII, or rFIX: In vitro and ex vivo analyses. J Thromb Haemost. 2021 Jul;19(7):1687-1696. [Content Brief]
[2]. Agersø H, et al. Pharmacokinetics of an anti-TFPI monoclonal antibody (concizumab) blocking the TFPI interaction with the active site of FXa in Cynomolgus monkeys after iv and sc administration. Eur J Pharm Sci. 2014 Jun 2;56:65-9. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Concizumab 関連分類
HY-P99283 関連分類
Powered by Bioz